Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 1983;61:429-432
© 1983 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MILEWICZ, A.
Right arrow Articles by KIRSCHNER, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MILEWICZ, A.
Right arrow Articles by KIRSCHNER, M. A.

Therapeutic Effects of Spironolactone in Polycystic Ovary Syndrome

ANDRZEJ MILEWICZ, MD, DANUTA SILBER, MD and MARVIN A. KIRSCHNER, MD

From the Department of Endocrinology, Institute of Internal Diseases, Medical Academy, Wroclaw, Poland; and Newark Beth Israel Medical Center-New Jersey Medical School, Newark, New Jersey

Abstract

The authors examined the effect of three months' treatment with spironolactone in 34 women with polycystic ovary syndrome. In all patients a significant decrease in hirsutism was noted as well as restoration of a regular although anovulatory menstrual pattern. Plasma luteinizing hormone and follicle-stimulating hormone levels remained unchanged after spironolactone treatment; however, prolactin levels were lowered in both women with normal and those with elevated basal levels. Plasma testosterone, androstenedione, and dehydroepiandrosterone sulfate levels were decreased after three months of therapy. No side effects were observed. Plasma electrolytes and liver function tests were normal during the entire time of treatment. This therapy is recommended as initial nontoxic but effective treatment for women with polycystic ovary syndrome who are hirsute and have menstrual disturbances.




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
N. A Christy, A. S Franks, and L B. Cross
Spironolactone for Hirsutism in Polycystic Ovary Syndrome
Ann. Pharmacother., September 1, 2005; 39(9): 1517 - 1521.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. A. Ganie, M. L. Khurana, M. Eunice, M. Gulati, S. N. Dwivedi, and A. C. Ammini
Comparison of Efficacy of Spironolactone with Metformin in the Management of Polycystic Ovary Syndrome: An Open-Labeled Study
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2756 - 2762.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
E. Diamanti-Kandarakis, G. Tolis, and A. J. Duleba
Androgens and Therapeutic Aspects of Antiandrogens in Women
Reproductive Sciences, July 1, 1995; 2(4): 577 - 592.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by the American College of Obstetricians and Gynecologists.